FDA warned Nephron Sterile Compounding Center about insanitary sterile drug production and sterility assurance failures found in a 2022 inspection.
What happened
FDA inspected the West Columbia, SC outsourcing facility from March 28 to April 20, 2022, and issued a Form FDA 483. Investigators found about 1,686 microbial contamination excursions in the ISO 5 aseptic processing area without adequate corrective action or product evaluation, and media fills that did not simulate the largest batch size. The company later recalled some sterile drug products because of a lack of sterility assurance.
What FDA found
The facility did not take adequate corrective action or evaluate product impact after about 1,686 microbial contamination excursions in the ISO 5 aseptic processing area.
FDCA section 501(a)(2)(A)Media fills were not performed under the most challenging conditions, such as simulating the largest batch size, so there was no assurance of aseptic production.
FDCA section 501(a)(2)(A)The firm failed to establish an adequate system for monitoring environmental conditions in aseptic processing areas.
21 CFR 211.42(c)(10)(iv)The firm failed to conduct appropriate laboratory testing for each batch, as necessary, to be free of objectionable microorganisms.
21 CFR 211.165(b)The firm failed to thoroughly investigate unexplained discrepancies or failures of a batch or its components to meet specifications.
21 CFR 211.192The firm compounded drug products using glycopyrrolate bulk drug substance that was not on the 503B bulks list and was not used for a drug on the shortage list.
FDCA section 503B(a)(2)(A)
What FDA wants
FDA tells Nephron to notify the office in writing within 15 working days of the specific steps taken to address the violations, with explanations, supporting documentation, and any reason for delay.
Who should pay attention
- hospitals and clinics that buy compounded sterile drugs
- pharmacies or brands that source from this outsourcing facility
- quality teams at other 503B outsourcing facilities
This is a summary. Read the original letter on fda.gov.